Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2011. The report specifically addresses a notification of transactions involving directors and connected persons under the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding a specific personnel transaction rather than a financial results report.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The only change noted is an increase in the notional allocation of Ordinary share ADRs within the US Retirement Savings Plan due to a re-valuation of the cash element.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R (1)(c).
Important Facts for Investors
- Transaction Type: Increase in notional allocation of Ordinary share ADRs within the US Retirement Savings Plan.
- Director Involved: Dr M M Slaoui.
- Connected Person: Dr K Slaoui.
- Quantity: 2 ADRs.
- Transaction Date: December 9, 2011.
- Price: $44.66 per ADR.
- Notification Date: December 12, 2011.